Researchers at The University of Texas MD Anderson Cancer Center built a new atlas of lung cells, uncovering new cellular pathways and precursors in the development of lung adenocarcinoma, the most common type of lung cancer. These findings, published today in Nature, open the door for development of new strategies to detect or intercept the disease in its earliest stages.
Led by Humam Kadara, Ph.D., professor of Translational...
The University of Texas MD Anderson Cancer Center today announced it has acquired certain assets from Bellicum Pharmaceuticals,...
The University of Texas MD Anderson Cancer Center today was awarded 16 grants totaling over $25.5 million from the Cancer Prevention and Research...
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Recent developments at MD Anderson offer insights into drug-drug interactions for patients with acute...
A specific combination of targeted therapy and immunotherapy may better help patients with non-small cell lung cancer (NSCLC) overcome inherent...
Patients with soft-tissue sarcoma treated with neoadjuvant, or pre-surgical, immunotherapy had very little residual tumor at the time of surgery...
The University of Texas MD Anderson Cancer Center and C-Biomex Ltd. today announced a strategic research collaboration agreement to co-develop...
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...